• Aberdeen University Featured PhD Programmes
  • University of Pennsylvania Featured PhD Programmes
  • University of Cambridge Featured PhD Programmes
  • Staffordshire University Featured PhD Programmes
  • FindA University Ltd Featured PhD Programmes
  • University of Tasmania Featured PhD Programmes
University of Liverpool Featured PhD Programmes
University of Leeds Featured PhD Programmes
University College London Featured PhD Programmes
University of Liverpool Featured PhD Programmes
University of Tasmania Featured PhD Programmes

Discovering the mechanism of TRAIL sensitivity in mesothelioma

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Prof Janes
    Prof Walczak
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

Malignant mesothelioma (MM) is a rare, invariably fatal malignancy associated with asbestos exposure that occurs most frequently in the pleura. Treatment options are limited – the current gold standard chemotherapy regimen offers a median survival of 12.1 months versus 7 months for palliative therapy. There is thus a compelling need for more effective therapies.

TNF related apoptosis inducing ligand (TRAIL) is capable of inducing apoptosis selectively in cancer cells in vitro and in vivo. Whilst robust anti-cancer activity has been demonstrated in preclinical studies, results from clinical trials have proven disappointing. A number of reasons are possible including the absence of a validated biomarker for TRAIL sensitivity.

We have discovered a new biomarker for TRAIL sensitivity. This PhD project will delineate the mechanisms behind this with a view to building an application for a Phase1/2 study within the lifetime of the project.

Project aims:

1. To validate the biomarker / TRAIL effect in vitro through knock out and knock in studies in mutant and wild type (WT) MM cell lines.

2. To determine the mechanism by which biomarker alters TRAIL sensitivity in MM

3. To validate the biomarker / TRAIL effect in vivo using xenograft and genetically modified mouse models using recombinant TRAIL and available TRAIL agonists found safe in Phase1/2 studies

For informal enquiries please contact Professor Sam Janes: [email protected]

Eligibility

Physicians who are GMC-registered, meet UCL general admissions criteria, and qualify as UK/EU fee payers. These three year PhD studentships, funded by Cancer Research UK, includes a competitive clinical training salary, consumables funding, a travel allowance, and tuition fees (home/EU rate) paid in full.

Application procedure

To apply please e-mail the following pieces of information to [email protected] and provide the project number(s)* in the subject line.

1. A CV highlighting your academic achievement, clinical training, and research interest/experience, as well as stating your nationality and usual country of residence

2. A short summary (<500 words) detailing how your research interests and academic background matches the project

3. Contact details for two referees

*One application per candidate please. Although you may list more than one project per application, your short summary will need to specify how your background/interests fit each project.

Application Deadline: Applications accepted until 5.00pm 12th February 2015

Initial receipt of your application will be acknowledged. Short-listing and interviews to be done in February/March 2016. Queries about the application procedure or recruitment process should be directed to: [email protected]

How good is research at University College London in Clinical Medicine?

FTE Category A staff submitted: 449.74

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities
Share this page:

Cookie Policy    X